We investigate fundamental biology through an academic lens and with a business mindset


Immune and COVID-19 rejuvenation, HIV (Roman Regimen)

Completing IMPD stage (Q1 2023). First in Human dosing planned in late 2023 (Influenza vaccination of the elderly)



Pre-clinical studies in both stand alone protocols and in combination with check point inhibitors


Lifespan extension, Mitochondrial diseases

Drug discovery, Lead optimisation 2022


Alzheimer’s disease

Drug discovery, target validation 2022


Neurodegenerative disorders E.g.: Schizophrenia

Drug discovery, target validation 2022.


Autoimmune disorders

Drug discovery, lead optimisation. ®*, pending

We develop first-in class compounds to achieve human rejuvenation.

Contact Sentcell®

Go to contact